Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.005
https://www.valueinhealthjournal.com/article/S1098-3015(17)30338-8/fulltext
Title :
Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30338-8&doi=10.1016/j.jval.2017.08.005
First page :
A399
Section Title :
BREAKOUT SESSION I
Open access? :
No
Section Order :
3